reports
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on...
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024 NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company’s...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary F...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transforma...
- Sean Conroy
e-therapeutics - Termination of coverage
Edison Investment Research is terminating coverage on ABC Arbitrage (ABCA), paragon (PGN), Foresight Solar Fund (FSFL), Kendrion (KENDR), Lithium Power International (LPI), Triple Point Energy Transition (TENT), 4iG (4IG), e-therapeutics (ETX), Pharnext (ALPHA) and Shield Therapeutics (STX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant. Previously published reports can still be accessed via our web...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-H...
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential Company plans to initiate SERENITY At-Home pivotal Phase 3 safety trial with 120 mcg dose following recent meeting with FDA No FDA-approved therapies for acute treatment of agitation associated with bipolar disorders or schizophrenia in the home setting NEW HAVEN, Conn., April 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-...
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Tri...
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia Company plans to initiate trial following recent meeting with FDA No FDA-approved therapies for acute treatment of AAD are currently available NEW HAVEN, Conn., April 10, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced details regarding the planned design of its upcoming TRANQUIL...
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
BioXcel Therapeutics Announces $25 Million Registered Direct Offering NEW HAVEN, Conn., March 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 3,054,609 shares (the “Shares”) of common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants (the “Accompanying Warra...
Exscientia Business and Financial Update for the Full Year 2023
OXFORD, U.K.--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results for the fourth quarter and full year 2023, are summarised below. Exscientia will host a conference call Thursday, March 21 at 12:30 p.m. GMT / 8:30 a.m. EDT. “In 2023, we significantly expanded our technological capabilities with the opening of our automation facility, concentrated our internal research on high value oncology targets and steadily progressed multiple new and existing programmes with our large pharma partners...
BioXcel Therapeutics Announces European Patent Office’s Grant of Paten...
BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine Newly granted patent aligns with Company’s focus on expanding geographic coverage and strengthening intellectual property protection for BXCL501 NEW HAVEN, Conn., March 15, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today reported that the European Patent Office (EPO) granted the Co...
Exscientia présentera ses résultats financiers pour l’année 2023 le 21...
OXFORD, Angleterre--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) publiera ses résultats financiers pour le quatrième trimestre et l’exercice clos le 31 décembre 2023, le jeudi 21 mars 2024, avant l’ouverture des marchés américains. La société organisera une conférence téléphonique et une diffusion Web à 12h30 GMT / 8h30 EDT pour donner des nouvelles sur ses activités et examiner ses résultats financiers. Une diffusion Web de la conférence téléphonique en direct est accessible dans la section « Investisseurs et médias » du site Web de la société, sur . Il est également possible d’accéder à...
Exscientia to Report Full Year 2023 Financial Results on March 21, 202...
OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) will report financial results for the fourth quarter and full year ended December 31, 2023, on Thursday, March 21, 2024, before the open of U.S. markets. The Company will host a conference call and webcast at 12:30 p.m. GMT / 8:30 a.m. EDT to provide a business update and review financial results. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at . Alternatively, the live conference call can be accessed by dialing +1 (888) 596 4144 (U.S.), +44 (800) 358 0970 (U....
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter ...
BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023 Provides update on two late-stage clinical programs for BXCL501 for potential treatment of agitation Recently completed meetings with U.S. Food and Drug Administration for TRANQUILITY and SERENITY programs Conference call and webcast set for 8:00 a.m. ET today NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provi...
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Finan...
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 NEW HAVEN, Conn., March 01, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2023 financial results on Tues., March 12, 2024, before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET ...
Exscientia participera à de prochaines conférences d'investisseurs au ...
OXFORD, Angleterre--(BUSINESS WIRE)-- Exscientia plc (Nasdaq : EXAI) a annoncé aujourd'hui que des membres de sa direction participeront en mars prochain aux conférences suivantes destinées aux investisseurs : 44e conférence annuelle TD Cowen sur les soins de santé. Discussion informelle organisée le mercredi 6 mars 2024 à 14 h 10 EST (19 h 10 GMT) à Boston, Massachusetts 26e conférence annuelle Barclays sur les soins de santé. Discussion informelle organisée le mardi 12 mars 2024 à 13 h 05 HAE (17 h 05 GMT) à Miami, Floride Forum des investisseurs de KeyBanc Capital Markets en scienc...
Exscientia to Present at Upcoming Investor Conferences in March
OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March: TD Cowen 44th Annual Health Care Conference. Fireside chat on Wednesday, March 6, 2024 at 2:10 p.m. EST (7:10 p.m. GMT) in Boston, Massachusetts Barclays 26th Annual Global Healthcare Conference. Fireside chat on Tuesday, March 12, 2024 at 1:05 p.m. EDT (5:05 p.m. GMT) in Miami, Florida KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Fireside chat on Tuesday, March 19, 2024 at 2:15 p.m. EDT...
BioXcel Therapeutics Announces Termination of Proposed Public Offering
BioXcel Therapeutics Announces Termination of Proposed Public Offering NEW HAVEN, Conn., Feb. 13, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on February 8, 2024. As a result of such termina...
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 f...
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC) Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability BXCL701 is an investigational, oral innate immune activator designed to inflame the tumor microenvironment and augment CPI activity Company to discuss registration path at upcoming meeting with FDA NEW HAVEN, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel ...
BioXcel Therapeutics Announces Proposed Public Offering
BioXcel Therapeutics Announces Proposed Public Offering NEW HAVEN, Conn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, the Company expects to gran...
Exscientia lance une étude clinique pour approfondir l'évaluation de l...
OXFORD, Angleterre--(BUSINESS WIRE)-- Exscientia plc (Nasdaq : EXAI) annonce aujourd’hui le lancement d’EXCYTE-2, une étude clinique observationnelle sur la leucémie myéloïde aiguë (LMA) visant à étudier la relation entre la réponse ex vivo du médicament (EVDR) mesurée dans des échantillons de sang primaire ou de moelle osseuse à l’aide de la plateforme de médecine de précision unicellulaire basée sur l'apprentissage profond, et la réponse clinique réelle du patient. L’étude EXCYTE-2 collectera des échantillons de sang et de moelle osseuse de patients en première intention atteints de LMA, a...
Exscientia Initiates Clinical Study to Further Evaluate Functional Pre...
OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2, an observational clinical study in acute myeloid leukaemia (AML) to investigate the relationship between ex vivo drug response (EVDR) measured in primary blood or bone marrow samples using the company’s deep learning, single-cell precision medicine platform and actual patient clinical response. The EXCYTE-2 study will collect blood and bone marrow samples from first-line patients with AML, with an option to expand to second-line patients. Both patient groups represent areas of high un...
BioXcel Therapeutics Announces Completion of Patient Enrollment in Saf...
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA® Human proof of concept portion of the trial expected to begin in H1 2024; led by Georgetown Lombardi Comprehensive Cancer Center BXCL701 in combination with checkpoint inhibitor in preclinical studies demonstrated encouraging results in pancreatic cancer Initial study data expected in 2024 NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceuti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.